Abstract
Objectives and Scope
The intention of this study is to provide a detailed and thorough analysis of
the present and future global market for cancer therapeutics. This report
analyzes in detail the markets for colorectal cancer, prostate cancer, lung
cancer, breast cancer, leukemia and non-Hodgkin' s lymphoma. Therapies for
other types of cancer are discussed throughout the report, but are limited to
the Company Briefs chapter and various tables throughout the report. This
report from Arrowhead Publishers examines these major cancer markets in light
of newly emerging therapeutics, shifting market shares and line extensions for
major products on the market.
Reason for this study
The overall economic cost of cancer is staggering. The US National Institutes
of Health (NIH) estimates overall costs of cancer in the U.S. in 2006 at
$206.3 billion with $78.2 billion in direct medical costs. Further the WHO
predicts that global cases of cancer will rise to 15 million new cases by
2020, an increase of 50% over 2005' s rate. These staggering numbers indicate
the importance of effective therapies in treating this epidemic. There is
today still a strong need for therapies that
- more specifically target cancer cells
- extend progression-free survival rates
- provide patients with metastatic cancer better treatment options
What questions does this report answer
- What is the current market status of cancer therapeutics in general and
with regard to specific types of cancer?
- What are the strengths, weaknesses, opportunities and threats facing
various cancer therapeutics already on the market and ones still in the clinic?
- What are the major issues involved in the research and development of more
effective cancer therapeutics?
- Which new cancer therapeutics in development are nearing the market? And
how are they performing in the clinic?
Key features of this Report
- Market analysis of cancer therapeutics, by product, class, cancer type,
region/country and company
- SWOT (strengths, weaknesses, opportunities, threats) analysis for key
products on the market as well as for key emerging products
- A thorough overview of treatment regimens for various cancers, including
detailed information and analysis of first-line, second-line and third-line
treatment options
- Financial forecasts, by individual cancer therapy and cancer type
- Explanations of key technologies and mechanism of action of new classes of
cancer drugs
- Thorough descriptions of important areas of research and development in
cancer therapeutics and cancer vaccines
- Focused analysis of the global prevalence of cancer: incidence, mortality
and survival rates as they relate to new directions in cancer research
- Company briefs of stakeholders and companies active in cancer therapy R&D
- Over 145 tables/graphs analyzing the current and future market, disease
incidence and R&D pipelines for cancer therapeutics
- Presentation and analysis of clinical data underscoring success of key
therapies
- Market share data for leading companies and products in the field
- Profiles of leading products in the major cancer markets and analysis of
their market impact
| 
View Cart
